Our Mission.
We aim to establish our (Dual)-Hybrid-Nanoparticle technology as a superior drug-delivery platform, enabling pharmaceutical companies to enhance their drugs’ properties and gain regulatory approval faster.
Our mission is to help pharmaceutical companies overcome formulation challenges, achieve regulatory approval more efficiently, and ultimately improve therapeutic outcomes for patients, including better survival rates, fewer side-effects and quality of life. This is made possible by increasing drug concentrations at the site of action, using activated drugs, and applying specific targeting, all enabled by the unique properties of our (Dual)-Hybrid-Nanoparticle technology.
© Sven Pförtner / MedienService/ MPI-NAT
Our Vision.
We strive to be a trusted partner in overcoming formulation challenges, contributing to multiple successful drug approvals and improving both therapeutic outcomes and patients’ quality of life.
We provide a novel (Dual)-Hybrid-Nanoparticle technology as a superior alternative to existing delivery concepts, allowing dramatically higher drug loads, secure transport of sensitive drugs that cannot be applied until now, with an extraordinary flexibility regarding different drugs and drug combination with the ultimately goal to improve therapeutic outcomes for patients, including better survival rates, less side-effects and quality of life.
© Generated with Sora / OpenAI
Our Technology.
Our advanced (Dual)-Hybrid-Nanoparticle system designed for the efficient transport of high drug load and controlled release of pharmaceutical drugs within the body.
We developed two chemically distinct species, each optimized for specific classes of drugs, Hybrid- or Dual-Hybrid-Nanoparticle, with the drug being an integral part of the nanoparticle composition. They enable transport to target sites. After cellular uptake the drug is released gradually over an extended period in the presence of low pH, ensuring a sustained therapeutic effect.
Research - Medical Applications.
With over a decade of research behind it, our nanoparticle platform enables efficient drug delivery and improved efficacy across the following disease models.
About Us.
Science-based. Innovative. Versatile.
NanoDrug Delivery GmbH is an early-stage startup and university spin-off of Karlsruhe Institute of Technology, University Medical Center Göttingen, Max Planck Institute for Multidisciplinary Sciences with the aim to establish, further develop and commercialize our novel (Dual)-Hybrid-Nanoparticle technology. Our foundation: A diverse team of scientists and medical experts, bringing together decades of experience and worldwide partnerships.
© Henning Scheffen / Niedersachsen.next
_edited.jpg)
